Skip to Content


HT is a team of dedicated professionals who understand the business of science. As a preferred large molecule products and services organization, we operate with deep technical expertise COMBINED with a results-oriented mindset and a focus on project execution and delivery. Not your typical CRO, HT combines the speed and nimbleness of an entrepreneurial company with deep technical expertise you would typically see in large global organizations.

David Sunseri, Ph.D., President & Chief Executive Officer

David Sunseri, Ph.D. is President and Chief Executive Officer at Haematologic Technologies (HT).  David is responsible for leading the next phase of HT’s growth, solidifying and expanding HT’s position as a leading Contract Research Organization focused on large molecules and an innovator of biologic reagents and sample collection devices for research and diagnostic markets. 

David served as CEO of PMI BioPharma Solutions, a specialty CDMO providing protein-based research, target validation, functional characterization, advanced assay development, and GMP manufacturing services.   He led the company through a transition from pharmaceutical ownership to a private company focused on CRO and CDMO services until its sale to private equity in 2020. 

Prior to PMI, David spent almost four years at Berg, LLC, in positions of increasing responsibility leading all aspects of CMC during this time.  Most recently, he was the Vice President, Product Development responsible for clinical trial manufacturing, engineering operations, supply chain, and formulations.  Dave spent approximately 10 years with Schering-Plough and Merck in small molecule inhalation and parenteral development and commercial manufacturing of inhalation and medical device products. 

David received his bachelor’s degree in chemistry from the University of North Alabama and Ph.D. In Analytical Chemistry, specializing in Chromatography, from Florida State University under the direction of John G. Dorsey.

He serves on the University of North Alabama Foundation Board of Directors and is a member of the University of North Alabama’s College of Arts and Sciences advisory council

Scott Smythe, MBA, CPA, Chief Financial Officer

Scott Smythe is Chief Financial Officer at Haematologic Technologies LLC (HT).  Scott is responsible for all financial matters related to HT operations, including accounting, audit, treasury and corporate finance.  He is a member of the HT Senior Leadership Team and provides executive leadership to the Human Resource function.

Prior to joining HT, Scott served as Director of Finance in the Global Supply division of Pfizer Inc.  There he led the Finance teams supporting Global Quality Operations and Global Technology Services.  In his 25 years with Pfizer, Scott took on positions of increasing responsibility in internal audit, business development and strategic planning, commercial finance, business support and finally as Controller of the Brooklyn manufacturing site.

Earlier in his career, Scott served as the Controller/Chief Financial Officer for the Fisher Hotels Group.  He began his career as an auditor with PriceWaterhouseCoopers (PWC).

Scott received his BA in Chemistry from the University of Colorado at Boulder.  He received his MBA in Accounting from Rutgers University in Newark, NJ.  He is a member of the New York State Society of Certified Public Accountants.

Ryan Dorfman, Ph.D., Vice President, R&D Operations

Dr. Dorfman has over 25 years of experience in the field of Protein Biochemistry with expertise in Thrombosis and Hemostasis.  He is an accomplished scientist, project leader, and manager in the biotech industry. 

Dr. Dorfman received his B.S. degree in Biochemistry from Marietta College and his Ph.D. Degree in Biochemistry from Temple University.  Since completion of his Ph.D. degree in 2000, Dr. Dorfman began working for Haematologic Technologies, Inc. and has served as Senior Scientist, Scientific Director, and Vice President of R&D Operations.  Currently, he provides scientific leadership, for HT R&D Services and Reagent Manufacturing units.   


John Maddalena, Ph.D., Vice President

Dr.  Maddalena joined Haematologic Technologies in 1992, and was responsible for the development and implementation of a Quality Management System (QMS), and subsequent ISO 9001 registration, to support HT’s manufacturing activities.  More recently, Dr. Maddalena assumed oversight responsibilities for HT's GMP operations which focuses on providing GMP analytical testing services to support the development and release of protein therapeutics. He specializes in the development and validation of analytical test methods.

Dr. Maddalena received his B.S. in Microbiology from the University of Notre Dame, and his Ph.D. in Cellular and Molecular Biology from the University of Vermont.  Dr. Maddalena also holds a M.Ed. degree from the University of Massachusetts.

Vivian Bills, Director, HR and Finance

Ms. Bills joined Haematologic Technologies in 1995 and oversees the company’s functions of accounting, policies and procedures, financial analysis, and reporting. She is responsible for all administrative services including office services, human resources, and benefits management.

Ms. Bills received a Bachelor of Arts degree in English Literature from the University of Vermont.